Cytodyn Inc (CYDY)

[stockorus]

16 tables were not filed; I see tables for 8 out of 24 symptoms. Likely these 8 showed statistical significance (following their model) and 10 others showed "clinically meaningful improvement" as said in the PR. Agree that we cannot know what to make out for the actual numbers in those tables not shown, except that their end calculation showed something better for LL over placebo.

I also don't know what they mean by "baseline". Is that the score on starting day?

For the raw numbers in the shown tables, note the difference between baseline and Day 56 for LL arm vs placebo in the Severe case:

LL Placebo

joint pain 2 -> 0. 3 -> 1

tightness. 6 -> 0. 3 -> 2

Numbness. 5 -> 1. 1 -> 1

Weakness 5 -> 1. 4 -> 2

Sl. disturb. 10 -> 2. 8 -> 4

Headache. 5 -> 1. 4 -> 3

Short breath. 5 -> 0. 3->2

Nausea. 1 -> 0. 2 -> 0


Granted the entire evaluation of these things looks very subjective (patients scoring themselves?) etc., still for the above symptoms (other than nausea), in the severe case, the raw numbers show there is a MASSIVE improvement in the LL arm compared to placebo. How (looking at the full tables) are you concluding the raw numbers are not impressive?

Possibly by doing biomarker analysis, Dr. Recknor will deduce more detail behind the chemical activity of Leronlimab that caused these dramatic changes in the severe case for these symptoms.